INTRODUCTION: Arginine-vasopressin (AVP) and terlipressin (TP) are used as rescue drugs for states of shock and cardio-circulatory failure. METHODS: Review to assess AVP/TP as a rescue therapy in children with catecholamine-resistant shock or cardio-circulatory arrest. RESULTS: A total of 31 reports were included (428 patients); sixteen articles were case series, 10 case reports, 3 clinical evaluation studies, one study was a non-blind RCT while one study was a multicentre double-blind RCT. The most common indication for either drug was catecholamine-refractory septic shock (12 reports). Commonly reported responses following AVP/TP administration were a rapid increase in blood pressure, an increase in urine output, and a decrease in serum lactate. In most reports, AVP and TP led to the reduction of catecholamines. The cumulative mortality rate remained high (188/428; 43.9%) despite the use of AVP/TP. CONCLUSIONS: No firm recommendations on the use of AVP/TP in children with severe forms of cardio-circulatory failure can be issued.
INTRODUCTION: Arginine-vasopressin (AVP) and terlipressin (TP) are used as rescue drugs for states of shock and cardio-circulatory failure. METHODS: Review to assess AVP/TP as a rescue therapy in children with catecholamine-resistant shock or cardio-circulatory arrest. RESULTS: A total of 31 reports were included (428 patients); sixteen articles were case series, 10 case reports, 3 clinical evaluation studies, one study was a non-blind RCT while one study was a multicentre double-blind RCT. The most common indication for either drug was catecholamine-refractory septic shock (12 reports). Commonly reported responses following AVP/TP administration were a rapid increase in blood pressure, an increase in urine output, and a decrease in serum lactate. In most reports, AVP and TP led to the reduction of catecholamines. The cumulative mortality rate remained high (188/428; 43.9%) despite the use of AVP/TP. CONCLUSIONS: No firm recommendations on the use of AVP/TP in children with severe forms of cardio-circulatory failure can be issued.
Authors: Christopher W Mastropietro; Noreen F Rossi; Jeff A Clark; Haiping Chen; Henry Walters; Ralph Delius; Mary Lieh-Lai; Ashok P Sarnaik Journal: Crit Care Med Date: 2010-10 Impact factor: 7.598
Authors: Karen Choong; Desmond Bohn; Douglas D Fraser; Isabelle Gaboury; James S Hutchison; Ari R Joffe; Catherine Litalien; Kusum Menon; Patrick McNamara; Roxanne E Ward Journal: Am J Respir Crit Care Med Date: 2009-07-16 Impact factor: 21.405
Authors: James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers Journal: N Engl J Med Date: 2008-02-28 Impact factor: 91.245
Authors: Javier Urbano; Rafael González; Jorge López; María J Solana; José M Bellón; Marta Botrán; Ana García; Sarah N Fernández; Jesús López-Herce Journal: PLoS One Date: 2015-03-20 Impact factor: 3.240
Authors: Olivier Brissaud; Astrid Botte; Gilles Cambonie; Stéphane Dauger; Laure de Saint Blanquat; Philippe Durand; Véronique Gournay; Elodie Guillet; Daniela Laux; Francis Leclerc; Philippe Mauriat; Thierry Boulain; Khaldoun Kuteifan Journal: Ann Intensive Care Date: 2016-02-16 Impact factor: 6.925